Emerging roles of circular RNAs in liver cancer

Corentin Louis,1,† Delphine Leclerc,1,‡ Cédric Coulouarn1,*

Summary
Hepatocellular carcinoma and cholangiocarcinoma are the most common primary liver tumours, whose incidence and associated mortality have increased over recent decades. Liver cancer is often diagnosed late when curative treatments are no longer an option. Characterising new molecular determinants of liver carcinogenesis is crucial for the development of innovative treatments and clinically relevant biomarkers. Recently, circular RNAs (circRNAs) emerged as promising regulatory molecules involved in cancer onset and progression. Mechanistically, circRNAs are mainly known for their ability to sponge and regulate the activity of microRNAs and RNA-binding proteins, although other functions are emerging (e.g. transcriptional and post-transcriptional regulation, protein scaffolding). In liver cancer, circRNAs have been shown to regulate tumour cell proliferation, migration, invasion and cell death resistance. Their roles in regulating angiogenesis, genome instability, immune surveillance and metabolic switching are emerging. Importantly, circRNAs are detected in body fluids. Due to their circular structure, circRNAs are often more stable than mRNAs or miRNAs and could therefore serve as promising biomarkers – quantifiable with high specificity and sensitivity through minimally invasive methods. This review focuses on the role and the clinical relevance of circRNAs in liver cancer, including the development of innovative biomarkers and therapeutic strategies.

© 2021 The Authors. Published by Elsevier B.V. on behalf of European Association for the Study of the Liver (EASL). This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

Introduction
Circular RNAs (circRNAs) belong to a family of recently rediscovered RNA molecules. They are produced during the maturation of RNA transcripts. Structurally, circRNAs are covalently closed by a phosphodiester linkage between downstream donor and upstream acceptor RNA splice domains. Mainly considered as splicing errors during the past decade, circRNAs are now accepted as functional RNA molecules. They display tissue- and cell-specific expression patterns and are encoded from thousands of genes. Emerging evidence demonstrates that circRNAs are involved in biological processes contributing to the onset and progression of cancer. In addition, due to their circular structure, circRNAs are resistant to the action of exoribonucleases and therefore exhibit an expanded half-life compared to their parental linear counterparts, allowing detection even when expressed at a low level. It is estimated that exonic circRNAs are very stable in cells, with most species exhibiting a half-life of over 48 hours, compared to an average half-life of 10 hours for mRNAs. These properties suggest that circRNAs could represent clinically relevant biomarkers for the management of patients with cancer. This review specifically highlights recent discoveries on the functions and clinical relevance of circRNAs in liver cancer, including hepatocellular carcinoma (HCC) and cholangiocarcinoma (CCA).

CircRNA discovery, biogenesis and function
CircRNA discovery
CircRNAs were first discovered in 1976 on viroid particles. Then, circular structures were identified by electron microscopy in the cytoplasm of eukaryotic cells, notably in HeLa cells. Nevertheless, it was only in 1993 that circRNAs (circSry, a 1.3 kb circRNA derived from a single exon of the sex-determining region Y transcript in mice) were molecularly identified by dedicated experiments, including RNase H digestion followed by northern blotting, reverse-transcription PCR and sequencing. Afterward, several circRNAs previously described as “scrambled exon RNAs” were reported, including a circRNA from the rat cytochrome P450 2C24 gene. However, no specific biological function was reported for circRNAs at that time.

Next-generation sequencing (NGS) ushered in the beginning of the genome-wide identification of circRNAs. Traditional RNA-sequencing pipelines remove non-conventional reads that do not map with the reference genome, such as reads that arise from gene fusion or those originating from backsplicing events. New bioinformatic algorithms based on back-splice junction overlapping reads recognition made it possible to efficiently detect de novo circRNAs and to differentiate them from their

† These authors contributed equally to the work
* Corresponding author.
Address: Inserm UMR_S 1242, “Chemistry, Oncogenesis, stress, Signaling” (COSS), Centre de Lutte contre le Cancer Eugène Marquis, F-35042, Rennes, France. Tel.: +33-2-2323-3881.
E-mail address: cedric.coulouarn@inserm.fr (C. Coulouarn).
linear counterparts.\textsuperscript{12-15} In addition, novel specific protocols for NGS library preparation were established to enrich the RNA fraction with circRNAs, including ribosomal and polyA+ RNA depletion and RNase R treatment to degrade linear RNAs.\textsuperscript{16} Accordingly, the number of circRNA libraries drastically increased and repository databases (e.g. circBase) were established to annotate circRNAs.\textsuperscript{17} Recently, Xin et al. used rolling circle amplification followed by nanopore long read sequencing to decrypt full-length circRNA sequences, thereby increasing the roster of known circRNA isoforms.\textsuperscript{18} It is now accepted that circRNAs are the most abundant RNA isoforms, originating from thousands of human genes,\textsuperscript{19} and that their expression is conserved in eukaryotes.\textsuperscript{20}

CircRNA biogenesis

Contrary to their linear counterparts, circRNAs are generated by a non-canonical splicing mechanism, called back-splicing. A downstream 5’ splice donor site from a pre-RNA transcript reacts with an upstream 3’ splice acceptor site, which results in the 3’ extremity of a downstream exon joining to the 5’ extremity of an upstream exon. Therefore, the circularisation junction is formed of 2 mis-ordered exons (according to their genomic location). CircRNA back-splicing is an active process that can be promoted through various mechanisms (Fig. 1). For instance, many studies demonstrated that complementary inverted sequences localised into introns flanking the circularised exon junction could promote RNA circularisation.\textsuperscript{21,22} By hybridising to each other, inverted complementary sequences form a loop bringing distant splice sites into proximity, and thus facilitating back-splicing events. Further studies reported that circRNA biogenesis is driven by RNA-binding proteins (RBPs) located upstream and downstream of the circularised exons, promoting back-splicing by direct interaction or dimerisation. For example, by binding to specific intrinsic motifs, the RBP Quaking (QKI) induces circRNA biogenesis during epithelial-to-mesenchymal transition (EMT).\textsuperscript{23} It was further demonstrated that artificial insertion of QKI motifs was sufficient to induce back-splicing. Altogether,

\begin{figure}[h]
\centering
\includegraphics[width=\textwidth]{Fig1.png}
\caption{The biogenesis of circRNA. CircRNAs are generated by a non-canonical back-splicing, where a 5’ donor splice site (5’ss) of a downstream exon (here, exon 3, E3) will react with a 3’ acceptor splice site (3’ss) of an upstream exon (here, exon 2, E2), resulting in the formation of a unique back-splice junction that does not exist in linear RNA (here, the 5’ extremity of E2 with the 3’ extremity of E3). So far, 3 main mechanisms spearhead the RNA circularisation. (A) Lariat intermediate back-splicing. The back-splicing process occurs after alternative splicing generates an intermediate structure called a lariat, which includes the excluded exons (here, E2 and E3) and which can be secondly spliced. (B) Intrinsic base pairing. A direct physical proximity between distant splice sites allows the back-splicing process. This proximity is mediated by a complementary base pairing between the introns flanking the circRNA. (C) RBP interaction or dimerisation. Here, the physical proximity between 5’ss and 3’ss is mediated by RBP interaction/dimerisation located on the exons flanking the circularisation junction. These 3 main mechanisms result in the formation of either EcircRNA, ElcircRNA or IcircRNA. CircRNA, circular RNA; EcircRNA, exonic circRNA; ElcircRNA, exonic-intronic circRNA; IcircRNA, intronic circRNA; RBP, RNA-binding protein.}
\end{figure}
these data suggest that a combination of cis-acting elements and trans-acting factors bring into proximity a downstream 5' donor splice site with an upstream 3' splicing acceptor site, facilitating back-splicing events. Another so-called “lariat splicing” mechanism has also been reported to promote circRNA formation. During alternative splicing events, excluded exon(s) are incorporated into an intermediate circular lariat containing intron-exon structures, which could be spliced again to generate circRNAs7,11(Fig. 1). While the majority of circRNAs are only comprised of exonic sequences (EcircRNA), a substantial portion of circRNAs also include retained intronic sequences. The so-called exonic-intronic circRNAs (EicircRNAs) have been reported to interact with U1 small nuclear ribonucleoproteins (snRNP), thereby regulating the transcription of their parental gene.24 Likewise, some circRNAs consisting of only intronic sequences (icircRNAs; lariat-derived circRNAs) have been reported.25

CircRNA functions
Although circRNAs were discovered decades ago, defining their role remains a major challenge because of their low abundance and their sequence similarity with parental linear RNAs. To date, the most frequently reported mechanism of action of circRNAs is their capacity to sponge microRNAs (miRNAs) although other functions are emerging (e.g. transcriptional and post-transcriptional regulation, protein scaffolding) (Fig. 2).26,27 MiRNAs are small non-coding RNAs regulating gene expression at the post-transcriptional level. By binding the 3' untranslated regions of mRNAs, miRNAs repress mRNA translation and/or induce their degradation.28 Accordingly, miRNA abundance and activity are tightly regulated. Notably, miRNAs can be sequestered by RNA sponges, including circRNAs.29 Thus, CDR1 antisense circular RNA (circCDR1as) contains more than 70 miR-7 responsive elements. Through its sponging capability, circCDR1as acts as a competitive inhibitor of the tumour suppressor
miR-7, preventing it from binding to and repressing its natural targets involved in tumour promotion.22,30 However, this feature is uncommon. Indeed, an expanded identification and characterisation of circRNAs in mammals reported that circCDR1as is only 1 of 2 circRNAs with an over-representation of binding sites for a single miRNA.31 In addition, it should be noted that circCDR1as is detected in circular but not in linear form, complicating interpretations of its role as a sponge for mir-7.27 circRNA databases (e.g. CircInteractome, starBase) also predict the presence of circRNA/miRNA networks based on bioinformatics and/or experimental cross-linking immunoprecipitation (CLIP)-sequencing data.32,33 These databases also include information on RBP-circRNA interactions. Indeed, emerging evidence demonstrated that circRNAs can sponge RBPs, with functional consequences for their subcellular localisation and activity.34 For example, it was recently demonstrated that circFOXK2 interacts with YBX1 and hnRNPK to promote the expression of NUF2 and PDXK oncogenes in pancreatic cancer.35 In some cases, back-splicing also competes with canonical splicing. A typical example concerns muscleblind (MBL or MBNL1 in humans) RNA which contains several intronic motifs which the MBL protein can bind to. When overexpressed, MBL binds to these specific intronic RNA motifs, thus promoting an exon 2 back-splicing event and reducing its own protein expression as a feedback mechanism.36 Another study described a regulatory network involving YAP circRNA (circYAP) and its associated linear RNA. In breast cancer cell lines, it was demonstrated that circYAP interacts with YAP mRNA, PABP and the translation initiation protein eIF4G. This interaction inhibits the assembly of the translation initiation complex on YAP mRNA, resulting in the inhibition of translation.37 Interestingly, circRNAs can promote transcription of their parental gene by interacting with U1 snRNPs and the RNA polymerase II complex.38 It is also important to emphasise that circRNAs may be coding, as demonstrated in Drosophila by ribosome footprinting sequencing specifically focused on reads that overlap with specific circRNA circularisation junctions.39 Likewise, translation of circRNAs can be mediated by internal ribosome entry sites (IRES).40–41 In addition, emerging data suggest that circRNA translation could be driven by epitranscriptomic modifications, including N6-methyladenosine (m6A), in a cap-independent manner.42 Recent studies also demonstrated that the m6A modifications could distinguish self-circRNAs from immunogene foreign circRNAs (i.e. those coming from viruses).43 Although the functions of circRNAs have not been fully elucidated, it is clear that circRNAs contribute to the regulation of gene expression. Thus, one can assume that the deregulation of circRNAs under pathological conditions will greatly affect fundamental processes required to maintain cellular and tissue homeostasis.

Overview of circRNAs in cancer: mechanisms and clinical relevance

As reviewed in 2020, circRNAs are involved in physiological processes by regulating gene expression and protein activity.44 Growing evidence demonstrates that circRNAs are deregulated in cancer.2,4,44 Indeed, up- or downregulation of specific circRNAs correlates with clinical features like TNM stage, differentiation or survival.45 In addition, the ratio between the expression of circRNAs and the corresponding linear RNAs can be modified, suggesting that back-splicing is an actively regulated process involved in cancer. In 2019, a loss-of-function screen using small-hairpin RNAs (shRNAs) directed against highly expressed circRNAs indicated that 11.3% of circRNAs are necessary to promote cell growth in V16A prostate cancer cells. In contrast, among the related linear counterpart transcripts, 91.8% were not essential to fulfil this function.46 Thus, by exhibiting tumour suppressive or oncogenic activities, circRNAs may contribute to cancer onset and progression. As mentioned above, a well-described function of circRNAs is their capability to sponge miRNAs, thereby promoting or suppressing tumour progression, depending on the nature of the miRNA targets.47,48

Given that the field is still in its infancy, there is currently little overlap between studies, similar to what we observed years ago for miRNAs. Although the current literature has not yet enabled the identification of master oncogenic or tumour suppressive circRNAs, such as RAS or TP53 for coding genes, several circRNAs have been detected in multiple cancers (e.g. circHIPK3, circR5, circFOXO3, circMT01). One archetype of a possible oncogenic circRNA is circHIPK3, which harbours 18 binding sites for sponging 9 tumour suppressor miRNAs involved in cell growth in several cancers, including breast cancer, colorectal cancer and HCC.49 This observation has revealed new therapeutic opportunities, such as using target site blocker oligonucleotides to inhibit the sponging activity of circHIPK3. However, circHIPK3 was also reported to be downregulated in bladder cancer and involved in cell growth and metastasis inhibition, suggesting that circRNA function could be highly context-dependent, making it difficult to define a particular circRNA as oncogenic or tumour suppressive.45,50 Interestingly, circRNAs have also been shown to derive from master oncogenic or tumour suppressive genes, including circTP53, which was reported to promote colorectal cancer by sponging miR-876-3p and subsequently increasing cyclin-dependent kinase-like 3 expression.51 An exome capture RNA-sequecing project was recently conducted in more than 2,000 cancer samples, including cell lines, tumours from diverse organs and non-pathological tissues. Data were compiled into MiOncoCirc, the first international cancer-specific circRNA database.52

CircRNAs and the hallmarks of liver cancer

Liver cancer ranks sixth among the most prevalent cancers worldwide. Dramatically, both its incidence and associated mortality have steadily increased over the last decade. HCC and intrahepatic cholangiocarcinoma (iCCA) account for ~80% and ~15% of primary liver tumours, respectively.52–54 Both are associated with limited therapeutic options as they are frequently diagnosed late.53,54 Although our understanding of liver carcinogenesis has improved, notably through functional genomic studies, effective long-term targeted therapies are still lacking. By integrative genomics based on gene expression, the core transcriptional hallmarks of human HCC were previously highlighted, identifying potentially targetable signalling pathways that were commonly altered.55 In 2011, Hanahan and Weinberg updated the hallmarks of cancer and described 10 hallmarks that govern the evolution of normal cells to a neoplastic state in most cancers.56 Defining circRNAs that are involved in the hallmarks of liver cancer could provide new insights into liver carcinogenesis and open avenues for the development of new therapeutic options. However, to what extent circRNAs contribute to liver carcinogenesis still requires experimental investigations. In order to determine how circRNAs could contribute to liver cancer, we reviewed the current
literature on cancer hallmarks impacted by circRNAs (Fig. 3 and Table 1).

**Hepatocellular carcinoma**
Data from the recent literature suggest that circRNAs are relevant molecules involved in regulatory networks governing HCC onset and progression. While the role of circRNAs in cell proliferation, apoptosis, migration and invasion is rather well described, their role in angiogenesis, immune surveillance and metabolic switching is still under investigated. The involvement of circRNAs in enabling replicative immortality, another hallmark of cancer cells, has not been investigated in HCC.

**CircRNAs in cell proliferation and resistance to cell death**
Sustained proliferation is one of the distinguishing features of cancer cells. Some circRNAs exhibit tumour suppressor activities and display low expression in HCC (Table 1). For instance, circMTO1 was downregulated in HCC and was reported to sponge miR-9, a well-known oncogenic miRNA. Reduced expression of circMTO1 in HCC results in increased miR-9 activity, leading to reduced expression of its natural targets, such as the cell cycle inhibitor p21. Accordingly, circMTO1 suppresses HCC progression and low expression of circMTO1 predicts poor overall survival.\textsuperscript{47} Deregulation of cell proliferation pathways in HCC is also mediated by pro-oncogenic circRNAs. Among them, SCD-circRNA 2 was upregulated in HCC tissues. A gene regulatory network was proposed, in which the RBP RBM3 promotes HCC cell proliferation in a SCD-circRNA 2-dependent manner.\textsuperscript{57} Oncogenic circRHOT1 was also related to sustained HCC cell proliferation by recruiting TIP60 (also known as KAT5), a member of the MYST sub-family of histone acetyltransferases, to the promoter of NR2F6 and subsequently enhancing its transcription.\textsuperscript{58} Interestingly, NR2F6 has also been reported as a central intracellular immune checkpoint for cancer immune surveillance that suppresses adaptive anti-cancer immune responses.\textsuperscript{59} An

**Fig. 3. CircRNA functions in liver cancer onset and progression.** The upper part gathers the most described functions driven by circRNAs in liver cancer, while the lower part pinpoints potential emerging regulatory functions of circRNAs. Pro-oncogenic circRNAs are indicated in red and tumour suppressor circRNAs are indicated in green. CircRNAs deregulated in iCCA are marked by an asterisk. CircRNA, circular RNA; iCCA, intrahepatic cholangiocarcinoma.
| Liver cancer | circRNA ID | circRNA function | Sponged molecules | Regulated targets | Reported functions | Ref. |
|-------------|------------|------------------|-------------------|------------------|--------------------|-----|
| HCC         | SCD-circRNA2* | RBP interaction | N/A               | p-ERK †          | Sustaining proliferative signalling, invasion and metastasis | 57  |
| HCC         | circRHO1†    | transcription regulation | NRF26 TIP60 | NRF26 †         | Sustaining proliferative signalling, resisting cell death, invasion and metastasis | 58  |
| HCC         | circ-100338* | RBP interaction | N/A               | MMP9 †           | Sustaining proliferative signalling, invasion and metastasis | 110 |
| HCC         | circ-0000092* | miRNA sponging | miR-338-3p ‡      | HN1 †           | Sustaining proliferative signalling, invasion and metastasis, inducing angiogenesis | 71  |
| HCC         | circPRMT5†   | miRNA sponging | miR-188-5p ‡      | HK2 †           | Sustaining proliferative signalling, invasion and metastasis, deregulating cellular energetics | 111 |
| HCC         | circMAT2B†   | miRNA sponging | miR-338-3p ‡      | PKM2 †         | Sustaining proliferative signalling, invasion and metastasis, deregulating cellular energetics | 75  |
| HCC         | circASAP1†   | miRNA sponging | miR-326 ‡, miR-532-5p ‡ | MAPK1 †, CSF-1 † | Sustaining proliferative signalling, invasion and metastasis, tumour-promoting inflammation | 80  |
| HCC         | circβ-catenin* | translated, decoy | N/A       | β-catenin †     | Sustaining proliferative signalling, invasion and metastasis | 60  |
| HCC         | circUHRF1†   | miRNA sponging | miR-449c-5p ‡     | TIM3 †         | Sustaining proliferative signalling, immune surveillance escape | 112 |
| HCC         | circTRIM33-12* | miRNA sponging | miR-191 †       | 5hmC ‡          | Sustaining proliferative signalling, immune surveillance escape, invasion and metastasis | 77  |
| HCC         | circHIAT1†   | miRNA sponging | miR-3171 †       | PTEN ‡          | Sustaining proliferative signalling, evading growth suppressors, resisting cell death | 61  |
| HCC         | circLARP4†   | miRNA sponging | miR-761 †       | RUNX3 ‡, p53 ‡, p21 ‡ | Sustaining proliferative signalling, evading growth suppressors | 47  |
| HCC         | circMT5†     | miRNA sponging | miR-9 †         | p21 ‡           | Sustaining proliferative signalling, invasion and metastasis | 47  |
| HCC         | circTCH      | miRNA sponging | miR-224-5p ‡     | maF ‡          | Sustaining proliferative signalling, resisting cell death, genome instability and mutation | 65,113|
| iCCA        | circ-0000284* | miRNA sponging | miR-637 ‡       | LY6E †         | Sustaining proliferative signalling, resisting cell death, invasion and metastasis | 64  |
| iCCA        | circ-0005230* | miRNA sponging | miR-1238 ‡, miR-1299 ‡ | N/A           | Sustaining proliferative signalling, resisting cell death, invasion and metastasis | 63  |
| iCCA        | circACTN4†   | miRNA sponging | miR-424-5p ‡     | YAP †, FZD7 †  | Sustaining proliferative signalling, invasion and metastasis | 82  |
| iCCA        | circSMARCA5† | miRNA sponging | miR-127-5p ‡, miR-612 ‡, miR-4688 ‡ | SHPRH ‡ | Sustaining proliferative signalling, resisting cell death, invasion and metastasis | 66,67 |
| iCCA        | circSMARCA5† | miRNA sponging | miR-17-3p ‡, miR-181b-5p ‡ | TIMP3 ‡ | Sustaining proliferative signalling, invasion and metastasis | 48,61|

CircRNA, circular RNA; HCC, hepatocellular carcinoma; iCCA, intrahepatic cholangiocarcinoma; miR/miRNA, microRNA.

* In vivo functional confirmation in preclinical mouse models.
original mode of action of circβ-catenin, a circRNA derived from β-catenin, a well-characterised oncogene in liver cancer, has recently been reported.60 Indeed, circβ-catenin is translated into a 370-amino acid β-catenin isoform and acts as a decoy. This shorter isoform can stabilise full-length β-catenin by antagonising GSK3β-induced β-catenin phosphorylation and degradation, leading to activation of the Wnt pathway, and promoting tumour cell growth.50

Another well-described feature of tumour cells is their ability to evade anti-proliferative signals governed by tumour suppressor genes (i.e. quiescence, cell cycle arrest, senescence, cell death).56 Such properties are essential to maintain a pool of active transformed cells, notably by repressing or inactivating cell cycle regulators. For instance, a network involving circHIAT1, miR-3171 and the PTEN tumour suppressor gene was shown to contribute to HCC progression (Table 1). Thus, circHIAT1 downregulation in HCC was responsible for miR-3171 release, thereby promoting PTEN repression.61 Similarly, it was demonstrated that miR-671 activation, as a consequence of circLARP4 sponge downregulation, drives the silencing of master tumour suppressor genes RINX3, CDKN1A and TP53 in HCC.62

Programmed cell death by apoptosis is responsible for the removal of damaged cells. Notably, apoptosis serves as a bulwark against the propagation of transformed cells. Investigations into pro- and anti-apoptotic programmes will be critical to elucidate the pathways whereby tumours succeed in progressing to states of high-grade malignancy and resistance to therapy.56 Lately, circRNAs were reported for their entailment in signalling tracks governing the apoptotic machinery in liver cancer. Several studies identified circRNAs that can regulate apoptosis (Table 1). Pro-oncogenic circRNAs such as circRHO1, circ-0005230, or circ0000284 have all been shown to exert anti-apoptotic activity on HCC and iCCA cell lines. Through intrinsic miRNA sponging properties, these circRNAs promote tumourigenesis by preserving anti-apoptotic factors, such as NRF2 and LY6E, from degradation.54,63,64 Meanwhile, a decreased expression of circITCH and circ-0001649 contributes to cell death resistance by loosening the sponging of specific anti-apoptotic miRNAs. Thus, pro-apoptotic natural targets (e.g. MAFF and SHPRH) lack circRNA protection against miRNA degradation and are unable to counteract tumour cell spreading.65–67 Remarkably, most of these circRNAs are also involved in sustained abnormal cell proliferation, resulting in unbalanced cell homeostasis and cancer progression.

CircRNAs in invasion, metastasis and angiogenesis

Invasion and metastasis are tightly associated with EMT, a critical cellular process governing the plasticity of epithelial cells which lose adherent junctions, apico-basal polarity and acquire the abilities to resist apoptosis, to invade, and to disseminate.56,68 However, to what extent circRNAs are involved in acquiring mesenchymal features and a metastatic phenotype has not been extensively explored in liver cancer (Table 1). RNA-sequencing identified a signature of circRNAs that were significantly deregulated in HCC tissues, including circSMARCA5. Low expression of circSMARCA5 in HCC was associated to the regulation of DEAD-box helicase 9 (DHX9), an abundant nuclear RNA helicase, and was shown to promote HCC cell growth and metastasis. One mechanism of action resulting from the reduced expression of circSMARCA5 involved a decreased expression of the metalloproteinase inhibitor TIMP3 due to the increased activity of miR-17-3p and miR-181b-5p, 2 miRNAs naturally sponged by circSMARCA5. Further highlighting its importance in cancer, it was recently reported that circSMARCA5 can bind to its parent gene locus, forming an R-loop, which results in the downregulation of tumour-promoting SMARCA5 in breast cancer.68 In glioblastoma multiform, circSMARCA5 is also a tumour suppressor and acts as a decoy for SRSF1 (serine and arginine rich splicing factor 1) through a GAUGAA binding motif, thus controlling cell migration and angiogenesis, notably by regulating VEGFA mRNA splicing.70 In HCC, circSMARCA5 downregulation was associated with poor outcomes, including shorter overall and recurrence-free survival.43 The role of circRNAs in HCC metastasis was further evaluated by circRNA expression profiling in 15 patients who displayed pulmonary metastasis and 15 patients that did not show any metastasis or recurrence. Hence, circASAP1 was specifically upregulated in HCC with a high metastatic potential. Gain and loss of function experiments demonstrated that circASAP1 promotes HCC cell metastasis by acting as a competitive endogenous RNA for miR-326 and miR-532-5p, leading to the induction of their common targets, the kinase MAPK1/ERK2 and CSF1, also known as macrophage colony-stimulating factor (M-CSF). By regulating these 2 targets, circASAP1 modulates HCC cell proliferation, invasion and tumour-associated macrophage (TAM) infiltration.71 More recently, an original mechanism of action has been reported for circPABPC1, a tumour suppressive circRNA downregulated in HCC.71 Although circPABPC1 is predominantly localised in the cytoplasm, its small size (91 bases) makes it unlikely to be a miRNA sponge. Indeed, circPABPC1 functions as a protein scaffold for ITGB1, a key integrin involved in HCC metastasis. Frequent loss of circPABPC1 correlates with increased ITGB1 level in patients with advanced HCC. Mechanistically, circPABPC1 physically links ITGB1 to the proteasome 26S and promotes its degradation in a ubiquitin-independent manner, thereby reducing tumour cell adhesion, migration, and metastatic spreading.71

Tumour cell spreading requires a tailored vascular system to ensure its operational needs. Hence, during tumour progression, a new tumour-associated vasculature is generated by uncontrolled angiogenesis.65,72 In silico analysis suggested that circRNAs, including hsa_circ_0000092, could contribute to the tumour-associated angiogenic switch occurring during liver carcinogenesis (Table 1). Hsa_circ_0000092 is upregulated in HCC and significantly associated with shortened overall survival. A comprehensive analysis of both coding and non-coding RNAs suggested that hsa_circ_0000092 interferes with the negative regulation of haematopoietic- and neurologic-expressed sequence 1 (HN1) by miR-338-3p. Increased expression of oncogenic HN1 not only promotes HCC cell invasion and migration, but also angiogenesis.73

CircRNAs in metabolic switching

An important hallmark of cancer is the adjustment of energy metabolism to support cancer cell proliferation. During carcinogenesis, cells classically switch towards aerobic glycolysis to meet their energy demands. This typical glycolytic reprogramming is associated with well-known oncogenes.56,74 However, there is still little evidence regarding the role of circRNAs in this process (Table 1). Meta-analysis of gene expression datasets demonstrated that circMAT2B was upregulated in HCC (compared to paired adjacent normal tissues) and strongly associated with glycolysis. More specifically, circMAT2B promotes glycolysis-dependent cell proliferation and migration.
under hypoxic conditions both in vitro and in vivo. A regulatory axis was proposed in which circMAT2B positively regulates the miR-338-3p target gene pyruvate kinase M2, a key enzyme involved in glycolysis.\textsuperscript{73} CircMAT2B is also clinically relevant since its elevated expression is associated with shortened overall survival.\textsuperscript{75}

**CircRNAs in immune system surveillance escape and inflammation**

It has long been recognised that tumour onset and progression are continuously monitored by the immune system. Thus, proliferating tumour cells have somehow developed the capability to evade immune surveillance.\textsuperscript{56,76} A recent study pinpointed that circTRIM33-12 downregulation in HCC was correlated with poor clinical features, suggesting its potential utility as an independent HCC risk factor (Table 1). Mechanistically, circTRIM33-12 expression was negatively associated with cell proliferation, migration and invasion through the miR-191-dependent positive regulation of TET1 demethylase. In addition, circTRIM33-12 was shown to participate in immune evasion via the regulation of activating receptor NKG2D (natural-killer group 2 member D) ligands. Thus, circTRIM33-12 regulates natural killer cell-, γδ T cell- and CD8+ T cell-mediated immune responses to cancers.\textsuperscript{77}

Inflammation is an essential mechanism to protect the body against injuries and pathogenic microorganisms. Nevertheless, in the context of carcinogenesis, substantial evidence indicates that the immune system could exert tumourigenic properties.\textsuperscript{78} For instance, by releasing cytokines, infiltrated immune cells indirectly promote tumour growth and survival.\textsuperscript{79} One study reported the involvement of circRNAs in tumour-promoting inflammation in HCC (Table 1). Hence, it was highlighted that an enhanced expression of circASAP1 indirectly induces CSF1 expression, a macrophage mitogenic factor, by sponging miR-532 and miR-326, and therefore promotes TAM recruitment.\textsuperscript{80} There is growing evidence that TAM infiltration is strongly associated with tumour onset, progression and aggressiveness.\textsuperscript{79} Thus, circASAP1 could promote HCC development by participating in TAM infiltration.\textsuperscript{80}

**Intrahepatic cholangiocarcinoma**

Only few studies have reported on the role of circRNAs in iCCA so far (Table 1). One study focused on circSMARCA5, a tumour suppressor circRNA already largely described for its role in the progression of several cancers, including HCC. The expression of circSMARCA5 was reduced in iCCA tissues and negatively correlated with advanced TNM stage and overall survival. Overexpression of circSMARCA5 was further associated with decreased iCCA cell proliferation.\textsuperscript{81} Very recently, circACTN4 has been shown to be induced in iCCA and to promote tumour cell growth and metastasis by regulating the Hippo and Wnt signalling pathways. Interestingly, circACTN4 has been reported i) to act as a sponge for miR-424-5p which could target YAP in the cytoplasm and ii) to recruit YBX1 to initiate FZD7 transcription in the nucleus. This study implies that circACTN4 acts as a signalling nexus allowing for the coordinated activation of Hippo and Wnt pathways in iCCA.\textsuperscript{82} However, the dynamic regulation of circRNA shuttling between the nucleus and the cytoplasm, in relationship to their function, is an important feature which remains to be elucidated. A couple of other studies identified aberrantly expressed circRNAs in both CCA cell lines and resected iCCA tumours. Thus, circ-0001649 and circ-0005230 were respectively down- and upregulated in iCCA. These circRNAs were associated with cell proliferation, migration and invasion.\textsuperscript{63,67} Very recently, upregulation of circHMGC1-016 was also reported to contribute to iCCA development and immune tolerance through sponging miR-1236-3p to regulate CD73 and GAL-8 expression.\textsuperscript{83} Several circRNAs derived from CASC15, a transforming growth factor beta-induced long non-coding RNA, have also been associated with an inflammatory microenvironment in iCCA.\textsuperscript{84} Most of the studies reported so far have focused on circRNAs within iCCA tumours. Nevertheless, circRNA are also found circulating in body fluids (e.g. embedded in extracellular vesicles [EVs]) and could therefore provide promising clinical opportunities. For instance, the expression of circ-0000284 was increased in CCA cell lines, tissues and plasma EVs. The circ-0000284-enriched EVs produced by CCA cells were able to enhance migration, proliferation and invasion of the normal surrounding cells both in vitro and in vivo.\textsuperscript{84} These results not only highlight circRNAs as mediators of cellular communication but also as potentially promising biomarkers.

**Limitations and challenges in interpreting data on circRNAs**

While studies reporting on the functions of circRNAs in liver cancer are promising, it is important to point out that circRNAs’ sponge activity is the major mechanism investigated so far (Table 1). Many of these studies rely on the cytoplasmic location of the circRNA of interest as a rationale to investigate miRNA activity, although this is where most exon-encoded circRNAs are located.\textsuperscript{85} Most studies also look for evidence of sponge activity by searching for any predicted miRNA binding sites in the circRNA and correspondingly expressed miRNAs and/or looking for interaction of the circRNA with proteins from the RNA-induced silencing complex (RISC). Although these strategies suggest interactions, they do not demonstrate function and should be complemented with loss of function or depletion studies to validate a functional effect on miRNAs. It is also important to consider that essentially all of the sequences attributed to circRNAs are contained in the parental mRNA, so unless the circRNA is more abundant than the mRNA or is somehow locking the miRNA into the RISC, it is hard to understand the stoichiometry to explain how circRNAs can effectively act as sponges in many cases. Similarly, a circRNA contains the same mRNA sequence encoded by the same exons (with the exception of the back-splice) so that ectopic expression of circRNA and mRNA from the same gene could have the same effect. This point should be addressed in functional studies given that in many cases, the expression of circRNAs tends to follow the expression of the mRNAs, so increases in expression of circRNAs are usually associated with increased expression of mRNA. However, given that the median half-live of circRNAs is estimated to be at least 2 to 5 times higher than that of linear mRNA,\textsuperscript{5,67,86} one can hypothesise that the contribution of circRNA to RNA sponging activity is greater than that of their linear counterpart. Thus, the dynamic of mRNA splicing and translation, the half-life of circRNA vs. mRNA, as well as their subcellular location, should be considered, as these features may contribute to the differential sponge activity of circRNA vs. mRNA. Additional studies, including Ago-CLIP followed by long read sequencing without RNase R treatment, will be needed in the future to better understand the stoichiometry of each
Table 2. CircRNA as biomarkers for liver cancer diagnosis and prognosis.

| Liver cancer                  | circRNA ID               | Biological sample | Biomarker relevance | Ref. |
|-------------------------------|--------------------------|-------------------|---------------------|------|
| Upregulated circRNA           |                          |                   |                     |      |
| HCC (HBV related)             | circRNA-100338           | HCC tissue        | Prognostic          | 114  |
| HCC (HBV related)             | hasa_circ_0000976        | plasma            | Diagnostic          | 115  |
|                               | hasa_circ_0000750        |                   |                     |      |
|                               | hasa_circ_0000796        |                   |                     |      |
| HCC (HBV related)             | hasa_circ_0027089        | plasma            | Diagnostic          | 116  |
| HCC (early stage)             | circ-CDYL                | HCC tissue        | Surveillance biomarker, early diagnostic | 117  |
| HCC                            | circRNA cisRS-7 (Cdr1as) | HCC tissue        | Microvascular invasion | 118  |
| HCC                            | circ_0008490             | HCC tissue        | Prognostic          | 119  |
| HCC                            | circRHT01                | HCC tissue        | Prognostic          | 120  |
| HCC                            | circBIRC6                | HCC tissue        | Prognostic          | 121  |
| HCC                            | hasa_circ_0000517        | HCC tissue        | Prognostic          | 122  |
| HCC                            | hasa_circ_0128298        | HCC tissue        | Diagnostic, prognostic | 123  |
| HCC                            | hasa_circ_0091579        | HCC tissue        | Diagnostic, prognostic | 124  |
| HCC                            | hasa_circ_0016788        | HCC tissue        | Diagnostic, prognostic | 125  |
| HCC                            | hasa_circ_0056836        | HCC tissue        | Diagnostic, prognostic | 126  |
| HCC                            | hasa_circ_0005075        | HCC tissue        | Diagnostic, prognostic | 127  |
| HCC                            | hasa_circ_0091581        | HCC tissue        | Prognostic          | 128  |
| HCC                            | circ-10720               | HCC tissue        | Prognostic          | 129  |
| HCC                            | circRNA-101368           | HCC tissue        | Prognostic          | 130  |
| HCC                            | circMAT2B                | HCC tissue        | Prognostic          | 131  |
| HCC                            | circ_0000267             | HCC tissue        | Prognostic          | 132  |
| HCC                            | circ_001569              | HCC tissue        | Prognostic          | 133  |
| HCC                            | circRNA-104718           | HCC tissue        | Prognostic          | 134  |
| HCC                            | hasa_circ_0067934        | HCC tissue        | Prognostic          | 135  |
| HCC                            | SCD-circRNA 2             | HCC tissue        | Prognostic          | 136  |
| HCC                            | circRNA_0000502          | HCC tissue        | Prognostic          | 137  |
| HCC                            | circRTRM                 | HCC tissue        | Prognostic          | 138  |
| HCC                            | circPVT1                 | HCC tissue        | Prognostic          | 139  |
| HCC                            | circRNA MYLK             | HCC tissue        | Prognostic          | 140  |
| HCC                            | circABCB10               | HCC tissue        | Prognostic          | 141  |
| HCC                            | circ-ZNF652              | HCC tissue        | Prognostic          | 142  |
| HCC                            | hasa_circ_00103809       | HCC tissue        | Prognostic          | 143  |
| HCC                            | hasa_circ_0021093        | HCC tissue        | Prognostic          | 144  |
| HCC                            | hasa_circ_0000673        | HCC tissue        | Prognostic          | 145  |
| HCC                            | hasa_circRNA_103809      | HCC tissue        | Prognostic          | 146  |
| HCC                            | circZFR                  | HCC tissue        | Prognostic          | 147  |
| HCC                            | circMET                  | HCC tissue        | Prognostic          | 148  |
| HCC                            | circ-HOMER1              | HCC tissue        | Prognostic          | 149  |
| HCC                            | circFBX011               | HCC tissue        | Prognostic          | 150  |
| HCC                            | circ-TCF4.85             | HCC tissue        | Diagnostic          | 151  |
| HCC                            | circBACH1                | HCC tissue        | Diagnostic, prognostic | 152  |
| HCC                            | circRNA-SORE             | HCC tissue        | Sorafenib resistance | 153  |
| HCC                            | hasa_circ_0003998        | HCC tissue, plasma | Diagnostic, prognostic | 154  |
| HCC                            | circASAP1                | HCC tissue, plasma, plasma exosomes | Prognostic | 155  |
| HCC                            | circ-ZEB1.33             | HCC tissue, serum | Diagnostic, prognostic | 156  |
| HCC                            | circRNA_101237           | HCC tissue, serum | Prognostic, cisplatin resistance | 157  |
| HCC                            | circ-FOX1                | HCC tissue, serum | Diagnostic, prognostic | 158  |
| HCC                            | circ_0000798             | Peripheral blood mononuclear cells | Diagnostic, prognostic | 159  |
| HCC                            | circ-104075              | Serum             | Diagnostic          | 160  |
| HCC                            | hasa_circ_000224         | Serum             | Diagnostic          | 161  |
| HCC                            | circPTGR1                | Serum exosomes    | Prognostic          | 162  |
| CCA                            | circDr1as                | CCA tissue        | Prognostic          | 163  |
| Downregulated circRNA          |                          |                   |                     |      |
| HCC                            | hasa_circ_0001649        | HCC tissue        | Prognostic, diagnostic | 164  |
| HCC                            | circMTG1                 | HCC tissue        | Prognostic          | 165  |
| HCC                            | circZKSCAN1              | HCC tissue        | Diagnostic          | 166  |
| HCC                            | circSETD3               | HCC tissue        | Prognostic          | 167  |
| HCC                            | hasa_circ_0000567        | HCC tissue        | Diagnostic          | 168  |
| HCC                            | hasa_circ_0028502        | HCC tissue        | Diagnostic          | 169  |
| HCC                            | hasa_circ_0076251        | HCC tissue        | Diagnostic, prognostic | 170  |
| HCC                            | circ-TCH                | HCC tissue        | Prognostic          | 171  |
| HCC                            | hasa_circ_0068669        | HCC tissue        | Diagnostic, prognostic | 172  |
| HCC                            | hasa_circ_0003570        | HCC tissue        | Diagnostic, prognostic | 173  |
| HCC                            | hasa_circ_0078602        | HCC tissue        | Diagnostic, prognostic | 174  |
| HCC                            | hasa_circ_0004018        | HCC tissue        | Diagnostic          | 175  |
| HCC                            | circC3P1                | HCC tissue        | Prognostic          | 176  |

(continued on next page)
molecule implicated in the sponging of miRNAs. It should also be noted that even if the aforementioned studies performed experimental validations using animal models (subcutaneous injection of cancer-derived cell lines stably over- or under-expressing a specific circRNA), the readout of these experiments is mainly tumour growth. Therefore, even though in vivo experiments confirmed the tumour suppressive or pro-oncogenic role of circRNAs, further investigations are needed to validate their involvement in several of the hallmarks of cancer. This aspect could be critical if circRNAs’ function is context-dependent and should be considered in view of emerging strategies for specific knockdown of circRNAs in vivo.86

CircRNAs: clinical opportunities in liver cancer

CircRNAs are promising clinically relevant biomarkers
In addition to the new insights on their regulatory functions, circRNAs also provide good opportunities to improve the management of patients with liver cancer. Indeed, even if most circRNAs are expressed at a low level (roughly <10% of the expression of their linear counterpart),34 their circular structure provides a higher resistance to exonuclease activity and therefore an expanded half-life. Such intrinsic physical features mean that circRNAs could be promising diagnostic and prognostic biomarkers. In addition, circRNAs are found circulating in liquid biopsies (e.g. blood, urine, saliva, bile),268 either freely or embedded in EVs.268 A recent study demonstrated that circRNAs are more specifically enriched and stable in exosomes compared to host secretory cells.90 Therefore, exosomal circRNAs could be useful minimally invasive biomarkers. They provide clear benefits over protein biomarkers which are prone to degradation and present limited organ specificity.25 In addition, methodologies used for circRNA detection are usually more specific and sensitive than the immunohasayas commonly used for protein biomarkers.92 Indeed, as nucleic acids, circRNAs can be easily and specifically amplified by reverse-transcription quantitative PCR using specific primers overlapping the backsplice junction.44 It was further demonstrated that circRNAs display tissue- and cell-specific expression patterns,2 a feature which could be helpful for diagnosis. Thus, circRNAs appear as promising molecules for the management of patients with cancer, as they exhibit many of the features expected of a biomarker: they are often more stable than linear RNAs, including miRNAs, and require minimally invasive intervention to be detected in body fluids by specific and sensitive methods. Accordingly, several ongoing clinical trials are exploring circRNAs as biomarkers in cancer, including biliary tract cancers (e.g. NCT03334708, NCT04584996, NCT04792437). However, it should be noted that a high level of circRNAs from serum/plasma may also only reflect a high level of circulating cells, as was reported for miRNAs.3,93

CircRNAs for liver cancer diagnosis and prognosis

Recent profiling studies support the utility of circRNAs as potential diagnostic and prognostic biomarkers in patients with liver cancer (Table 2). However, these studies currently suffer from limited sample sizes; hence, a robust signature of circRNAs commonly deregulated in patients with liver cancer remains elusive. Despite this weakness, merging the results of 3 independent studies identified circ_104075 as a circRNA recurrently upregulated in tissues and sera of patients with HCC compared to healthy individuals.84 Its expression is particularly high in HCC compared to other types of cancer and liver disease, suggesting that it could represent a biomarker for HCC diagnosis.85 Further statistical analyses demonstrated that circ_104075 exhibited a better sensitivity and specificity than biomarkers commonly used to diagnose HCC, such as alpha-fetoprotein.84 Such observations could be practice changing given that alpha-fetoprotein serum dosage and ultrasound, which are routinely used to diagnose early stage HCC, sometimes lack precision.84 Thus, patients could benefit from these innovative specific biomarkers if they enable the early detection of HCC. Similarly, circCDYL was expressed during the early stages of HCC, and thus might be a clinically relevant biomarker for early diagnosis and surveillance in high-risk populations, including patients with hepatitis B or C infection and/or cirrhosis.95

The prognostic potential of circRNAs has also been reported in liver cancer. A recent meta-analysis in HCC highlighted a tight correlation between an elevated expression of pro-oncogenic circRNAs and poor clinical outcomes such as reduced overall survival.96 Two other studies reported that low expression of circMT01 and circSETD3 in HCC was significantly associated with poor prognosis.47,97 In the same vein, it was shown that low levels of circSMARCA5 in icca correlate with poor overall survival. Interestingly, overexpression of circSMARCA5 in icca cell lines improves chemosensitivity to gemcitabine and cisplatin.81 Likewise, downregulation of circ_0003418 resulted in cisplatin resistance in HCC cells through activation of the Wnt/β-catenin pathway.98 Lately, circRNA-SORE was reported to mediate sorafenib resistance in HCC by stabilising YBX1, a master oncogenic factor. CircRNA-SORE acts by trapping YBX1 and thus, preventing its degradation by the E3 ubiquitin system. More interestingly,

---

**Table 2 (continued)**

| Liver cancer | circRNA ID (ID, Name) | Biological sample | Biomarker relevance | Ref. |
|--------------|------------------------|-------------------|---------------------|-----|
| HCC          | circTRIM33-12          | HCC tissue        | Prognostic          | 77  |
| HCC          | hsa_circ_0091570       | HCC tissue        | Diagnostic, prognostic | 169 |
| HCC          | circRNA_101505         | HCC tissue        | Prognostic cisplatin resistance | 700 |
| HCC          | circhIAT               | HCC tissue        | Prognostic          | 61  |
| HCC          | circADAMTS13           | HCC tissue        | Prognostic          | 171 |
| HCC          | circ-EPHB4 hsa_circ_0001730 | HCC tissue | Diagnostic          | 52  |
| HCC          | circSMARCA5            | HCC tissue, plasma | Diagnostic, prognostic | 48,173 |
| HCC          | circAD03               | HCC tissue, plasma | Diagnostic, prognostic | 174 |
| HCC          | hsa_circ_0001445       | Plasma             | Diagnostic          | 175 |
| HCC          | hsa_circ_0051443       | Plasma exosomes    | Diagnostic          | 196 |
| HCC          | hsa_circ_000156        | Serum              | Diagnostic          | 197 |
| HCC          | hsa_circ_000520        | Serum              | Diagnostic, prognostic | 52  |

CCA: cholangiocarcinoma; CircRNA: circular RNA; HCC: hepatocellular carcinoma.
CircRNA-SORE-related features spread across cancer cells through exosomal communication. These observations raise the possibility of developing innovative circRNA biomarkers to predict response to therapy.

CircRNAs as companion biomarkers for targeted therapies in liver cancer

Several targeted therapies are currently under clinical evaluation in liver cancer. In this context, the development of robust diagnostic tools to select the most suitable personalised therapy could be valuable. In HCC, nivolumab, an immune checkpoint inhibitor targeting PD-1, was approved by the FDA in 2017. However, objective anti-tumour response rates were only 15-20%. Therefore, a circRNA signature predictive of anti-PD1 response might be relevant. This innovative concept involving the development of companion biomarker tests from circRNA signatures may represent a breakthrough to guide targeted therapies. So far, to the best of our knowledge, there is no published report of circRNAs as companion biomarkers and/or theranostic targets that can predict response to a specific therapy, either in HCC or in iCCA.

Future directions: circRNAs and therapeutic opportunities

As mentioned above, there is growing evidence showing that circRNAs are deregulated in cancer and contribute to the regulation of oncogenic processes (Fig. 3). Thus, circRNAs might be considered as relevant therapeutic targets in cancer. The singularity of circRNA regulatory functions offers various opportunities to regulate their action during tumour progression and therefore, to develop innovative therapeutic strategies.

The pro-oncogenic activity of numerous circRNAs relies on sponging of tumour suppressor miRNAs. Thus, several strategies could be developed to reduce this pro-oncogenic activity, including the development of specific target site blockers (TSBs). TSB antisense oligonucleotides (ASOs) could be designed to target miRNA response elements carried by circRNAs. Thus, by competitive binding, TSBs could restore the tumour suppressor activity of a given miRNA. Although this strategy has not been applied to circRNAs yet, it showed great efficacy when applied to linear RNA sponges in vitro and in vivo. Another strategy aiming at directly decreasing circRNA abundance could be even more efficient. For that purpose, antisense locked nucleic acid gapmers specifically targeting the back-splice junction of circRNAs could switch off the expression of a specific circRNA without affecting the expression of the parental linear RNA. Several studies already demonstrated the efficacy of this approach not only with gapmers, but also with small-interfering RNAs and shRNAs. Besides, it was shown that circHIPK3 silencing in mice via adeno-associated virus shRNA could alleviate diabetic proliferative retinopathy. CRISPR/Cas13-based RNA editing systems could also be used to specifically silence circRNA activity. In addition, the abundance of pro-oncogenic circRNAs could be modulated at an upstream level by interfering with the splicing machinery to control the occurrence of back-splicing events. Indeed, it was already reported that circRNA biogenesis during EMT is tightly regulated by the RBP splicing factor QKI. Thus, one could hypothesise that modulating the expression level of a specific RBP could control the expression of circRNAs. Otherwise, as indicated above, there is strong evidence that circRNA biogenesis is mediated by hybridisation of complementary
intrinsic regions flanking circRNA sequences.\textsuperscript{21,22} Thus, one might anticipate that targeting these complementary sequences on pre-messenger RNAs using ASOs may block circRNA biogenesis by preventing the interaction of back-spliced regions. On the contrary, ASOs targeting key splice domains could be designed to enhance circRNA biogenesis. Recently, a base editing strategy targeting key back-splice domains showed great efficacy to specifically repress circRNA expression without affecting the linear counterpart RNAs (bioRxiv; https://doi.org/10.1101/2021.08.05.455347). This study provides an efficient method to deplete circRNAs for functional studies.

Nucleic acid-based therapeutics represent a promising approach in cancer. To date, several RNA-based drugs like ASOs are already FDA approved, and many are under clinical evaluation,\textsuperscript{105} paving the way for circRNA-based therapeutics. Indeed, circRNAs are often more stable than mRNA or miRNA molecules, and methods have already been developed to produce synthetic circRNAs.\textsuperscript{106} The advantage of this approach is the possibility of designing specific circRNAs. For example, a synthetic circRNA containing 5 binding sites for miR-21, an overexpressed onco-miRNA, was shown to effectively suppress miR-21 activity and to induce apoptosis in gastric cancer cell lines.\textsuperscript{107} Similarly, synthetic circRNAs could be designed to sequester oncoproteins. Indeed, a specific artificial circRNA able to sequester and inactivate the RBP hnRNP has already been engineered.\textsuperscript{108}

Conclusions
A plethora of therapeutic strategies are being developed to target circRNAs in liver cancer. Although proof-of-concept studies have reported promising results, it must be taken into account that circRNAs are still newly described protagonists in cancer onset and progression. Indeed, a great deal of effort is needed to fully understand the physiological roles, the regulatory functions and the biogenesis of circRNAs. A better understanding of these molecular mechanisms will provide a deeper insight into the specific role of circRNAs in the whole RNA regulatory network governing cancer hallmarks. This knowledge could eventually pave the way for circRNA-mediated molecular therapies and for clinically relevant biomarkers in liver cancer (Fig. 4). Thus, as an emerging field, circRNAs represent a wealth of opportunities for future research.

Abbreviations
ASO, antisense oligonucleotide; CCA, cholangiocarcinoma; circRNA, circu- lar RNA; CLIP, cross-linking immunoprecipitation; EMT, epithelial-to- mesenchymal transition; EVs, extracellular vesicles; HCC, hepatocellular carcinoma; H1N1, haematopoietic- and neurologic-expressed sequence 1; IRES, internal ribosome entry sites; miRNA, microRNA; NGS, next-generation sequencing; QKI, Quaking; RBP, RNA-binding protein; RISC, RNA-induced silencing complex; shRNA, small-hairpin RNA; snRNPs, small nuclear ribonuclear proteins; TAM, tumour-associated macrophage; TSB, target site blockers.

Financial support
The authors are supported by Inserm, Université de Rennes 1, Ministère de l’Enseignement Supérieur, de la Recherche et de l’Innovation, Ligue Contre le Cancer (CD22, CD35, CD85), Fondation ARC, INCa and ITMO Cancer AVIESAN (Alliance Nationale pour les Sciences de la Vie et de la Sante) dans le cadre du Plan cancer (Non-coding RNA in cancerology: Cancer AVIESAN (Alliance Nationale pour les Sciences de la Vie et de la Sante) dans le cadre du Plan cancer (Non-coding RNA in cancerology: biogenesis, function, and clinical significance. Trends Cancer 2020;6:319–336.

Conflicts of interest
The authors declare no competing interest.

Authors’ contributions
All the authors contributed to all aspects of the work. CL and DL contributed equally as co-first authors.

Supplementary data
Supplementary data to this article can be found online at https://doi.org/10.1016/j.jhepr.2021.100413.

References
Author names in bold designate shared co-first authorship

\[\text{1} \] Salzman J, Chen RE, Olsen MN, Wang PL, Brown PO. Cell-type specific features of circular RNA expression. Plos Genet 2013;9:e1003777.

\[\text{2} \] Li J, Sun D, Pu W, Wang J, Peng Y. Circular RNAs in cancer: biogenesis, function, and clinical significance. Trends Cancer 2020;6:319–336.

\[\text{3} \] Dragomir M, Calin GA. Circular RNAs in cancer - lessons learned from microRNAs. Front Oncol 2018;8:179.

\[\text{4} \] Kristensen LS, Hansen TB, Veno MT, Kjems J. Circular RNAs in cancer: opportunities and challenges in the field. Oncogene 2018;37:555–565.

\[\text{5} \] Vo JN, Cieslak M, Zhang Y, Shukla S, Xiao L, Zhang Y, et al. The landscape of circular RNA in cancer. Cell 2019;176:869–881 e813.

\[\text{6} \] Jeck WR, Sharpless NE. Detecting and characterizing circular RNAs. Nat Biotechnol 2014;32:453–461.

\[\text{7} \] Jeck WR, Sorrentino JA, Wang K, Slevin MK, Burd CE, Liu J, et al. Circular RNAs are abundant, conserved, and associated with ALU repeats. RNA 2013;19:141–157.

\[\text{8} \] Sanger HII, Klotz G, Riesner D, Gross HJ, Kleinschmidt AK. Viroids are single-stranded covalently closed circular RNA molecules existing as highly base-paired rod-like structures. Proc Natl Acad Sci U S A 1976;73:3852–3856.

\[\text{9} \] Khrustalny M, Podolsky S, Ragusa M, Turchi J, Khrustalny M, Podolsky S, Ragusa M, Turchi J, et al. The landscape of circular RNA in cancer. Cell 2019;176:869–881 e813.

\[\text{10} \] Hsu MT, Coca-Prados M. Electron microscopic evidence for the circular form of RNA in the cytoplasm of eukaryotic cells. Nature 1979;280:339–340.

\[\text{11} \] Capel B, Swain A, Nicoll S, Hacker A, Walter M, Koopman P, et al. Circular transcripts of the testis-determining gene Sry in adult mouse testis. Cell 1993;73:1019–1030.

\[\text{12} \] Zaphiropoulos PG. Circular RNAs from transcripts of the rat cytochrome P450 2C24 gene: correlation with exon skipping. Proc Natl Acad Sci U S A 1996;93:6536–6541.

\[\text{13} \] Hoffmann S, Otto C, Dooge G, Angerer A, Langenberger D, Christ S, et al. A multi-split mapping algorithm for circular RNA, splicing, trans-splicing and fusion detection. Genome Biol 2014;15:R34.

\[\text{14} \] Ma XK, Wang MR, Liu C, Dong R, Carmichael GG, Chen LL, et al. CIR- Cexplorer3: a CLEAR pipeline for direct comparison of circular and linear RNA expression. Genomics Proteomics Bioinformatics 2019;17:511–521.

\[\text{15} \] You X, Conrad TO. Acfs: accurate circRNA identification and quantification from RNA-Seq data. Sci Rep 2016;6:38820.

\[\text{16} \] Cheng J, Metge F, Dieterich C. Specific identification and quantification of circular RNAs from sequencing data. Bioinformatics 2016;32:1094–1096.

\[\text{17} \] Szabo L, Salzman J. Detecting circular RNAs: bioinformatic and experimental challenges. Nat Rev Genet 2016;17:679–692.
cholangiocarcinoma cells. Biochem Biophys Res Commun 2018;496:455–461.
[68] Qi J, Antin P, Brex D, Blainpan C, Brabtler T, Bronner M, et al. Guide-
lines and definitions for research on epithelial-mesenchymal transition. Nat Rev Mol Cell Biol 2020;21:341–352.
[69] Xu X, Zhang J, Tian Y, Gao Y, Dong X, Chen W, et al. CircRNA inhibits DNA damage repair by interacting with host gene. Mol Cancer 2020;19:128.
[70] Barbagallo D, Caponnetto A, Barbagallo C, Battaglia R, Mirabella F, Brex D, et al. The GAUCAG motif is responsible for the binding between circSMARCA5 and SRFS1 and related downstream effects on glioblasto-
toma multiforme cell migration and angiogenic potential. Int J Mol Sci 2021;22.
[71] Shi L, Liu B, Shen DD, Yan P, Zhang Y, Tian Y, et al. A tumor-suppressive circular RNA mediates uncanonical integrin degradation by the protea-
some in liver cancer. Sci Adv 2021;7.
[72] Morse MA, Sun W, Kim R, He AR, Abada PB, Mynderse M, et al. The role of angiogenesis in hepatocellular carcinoma. Clin Cancer Res 2019;25:912–920.
[73] Pu J, Wang J, Li W, Yu Y, Long X, et al. hsa_circ_0000092 promotes hepatocellular carcinoma progression through up-regulating HNF1 expression by binding to microRNA-338-3p. J Cell Mol Med 2020.
[74] Bergers G, Fengt SM. The metabolism of cancer cells during metastasis. Jhunjhunwala S, Hammer C, Delamarre L. Antigen presentation in can-
cer: insights into tumour immunoigenuity and immune evasion. Nat Rev Cancer 2021;21:298–312.
[75] Zhang PF, Wei CY, Huang XY, Peng R, Yang X, Lu JC, et al. Circular RNA circIRM53-12 acts as the sponge of microRNA-191 to suppress hepa-
tocellular carcinoma progression. Mol Cancer 2019;18:105.
[76] Greten FR, Grivennikov SI. Inflammation and cancer: triggers, mecha-
nisms, and consequences. Immunity 2019;51:27–41.
[77] Taniguchi S, Elhanse A, van Duzer A, Kumar S, Leitenberger JJ, Oshimori N. Tumor-initiating cells establish an IL-33-TGF-beta niche signaling loop to promote cancer progression. Science 2020;369.
[78] Hu QZ, Zhou SL, Li J, Zhou ZJ, Wang PC, Xiong XY, et al. Circular RNA sequencing identifies CircASAP1 as a key regulator in hepatocellular carcinoma metastasis. Hepatology 2020;72:906–922.
[79] Lu Q, Fang T. Circular RNA SMARCA5 correlates with favorable clinical tumor features and prognosis, and increases chemotherapy sensitivity in intrahepatic cholangiocarcinoma. J Clin Lab Anal 2020;34:e23138.
[80] Chen Q, Wang H, Liu F, Liang L, Zou Y, et al. Circular RNA ACTN4 promotes intrahepatic cholangiocarcinoma progression by recruiting YBX1 to initiate Fzd7 transcription. J Hepatol 2021.
[81] Xu YP, Dong ZN, Wang SW, Zheng YM, Zhang C, Zhou YQ, et al. circMRMC51-016 reshapes immune environment by sponging mir-1236-3p to regulate CD73 and GAL-8 expression in intrahepatic cholangiocarcinoma. J Exp Clin Cancer Res 2021;40:290.
[82] Merdrignac A, Angenard G, Allain C, Petitjean K, Bergeat D, Bellaud P, et al. A novel transforming growth factor beta-induced long noncoding RNA promotes an inflammatory microenvironment in human intra-
hepatic cholangiocarcinoma. Hepatol Commun 2018;2:254–269.
[83] Enukia Y, Luiolola M, Feldman ME, Sas-Chen A, Ulitsky I, Varden Y. Circular RNAs are long-lived and display only minimal early alterations in response to a growth factor. Nucleic Acids Res 2016;44:1370–1383.
[84] Pamudurti NR, Patop IL, Krishnamoorthy A, Ashwal-Fluss R, Bartok O, Kadener S. An in vivo strategy for knockdown of circular RNAs. Cell Discov 2020;6:52.
[85] Liu B, Song F, Yang Q, Zhou Y, Shao C, Shen Y, et al. Characterization of tissue-specific biomarkers with the expression of circRNAs in forensi-
cally relevant body fluids. Int J Leg Med 2019;133:1321–1331.
[86] Liao C, Deng Z, Chen Y, Moulaouin C. Exosomal circRNAs: new players in the field of cholangiocarcinoma. Clin Sci (Lond) 2019;133:2239–2244.
[87] Li Y, Zheng Q, Bao C, Li S, Guo W, Zhao J, et al. Circular RNA is enriched and stable in exosomes: a promising biomarker for cancer diagnosis. Cell Res 2015;25:981–984.
Cheng F, Wang L, Cheng J, Chen T. Up-regulation of hsa_circ_0005517 predicts adverse prognosis of hepatocellular carcinoma. Front Oncol 2019;9:1105.

Chen D, Zhang C, Lin J, Song X, Wang H. Screening differential circular RNA expression profiles reveal that hsa_circ_0128298 is a biomarker in the diagnosis and prognosis of hepatocellular carcinoma. Cancer Manag Res 2018;10:1275–1283.

Chang C, Zhang C, Lin J, Wang H. Circular RNA Hsa_Circ_0001579 serves as a diagnostic and prognostic marker for hepatocellular carcinoma. Cell Physiol Biochem 2018;51:290–300.

Guan Z, Tan J, Gao W, Li X, Yang Y, Li X, et al. Circular RNA hsa_circ_0016788 regulates hepatocellular carcinoma tumorigenesis through miR-486/CDK4 pathway. J Cell Physiol 2018;234:500–508.

Cheng F, Wang L, Zhang J. Circular RNA hsa_circ_0016788 displays as a biomarker for tumor progression and poor prognosis in surgical hepatocellular carcinoma patients. J Clin Lab Anal 2020;34:e23300.

Sun P, Fan X, Hu F, Xu W, Wei Q, Zang Y. circPCNX and pecanex promote hepatocellular carcinoma cell viability by inhibiting miR-506. Cancer Manag Res 2019;11:10957–10967.

Li Z, Liu Y, Yan J, Zeng Q, Hu Y, Wang H, et al. Circular RNA hsa_circ_0056836 functions an oncogenic gene in hepatocellular carcinoma through modulating miR-766-3p/PDFS2 axis. Aging (Albany NY) 2020;12:2485–2497.

Zhang S, Li G, Liu H, Li T, Liu J, Zhao Q, et al. Comprehensive circular RNA profiling reveals that hsa_circ_0005075, a new circular RNA biomarker, is involved in hepatocellular carcinoma development. Medicine (Baltimore) 2016;95:e3811.

Yang X, Song H, Zi Z, Kou J, Chen S, Dai Y, et al. Circ_0005075 promotes hepatocellular carcinoma progression by suppression of microRNA-335. J Cell Physiol 2019;234:1937–1946.

Wei X, Zheng W, Tian P, He Y, Liu H, Peng M, et al. Oncogenic hsa_circ_0015181 promotes the malignancy of HCC cell through blocking miR-526b from degradation by HCO3 mRNA. Cell Cycle 2020;19:817–824.

Meng J, Chen S, Han JX, Qian B, Wang XR, Zhong WL, et al. Twist1 regulates vimentin via circU22 circular RNA to promote EMT in hepatocellular carcinoma. Cancer Cell Int 2019;19:234.

Li S, Gu H, Huang Y, Peng Q, Zhou R, Yi P, et al. Circular RNA R10368/miR-200a axis modulates the migration of hepatocellular carcinoma through HMBG1/RAGE signaling. Cell Cycle 2017;17:2349–2359.

Pan H, Tang L, Jiang H, Li X, Wang R, Gao J, et al. Enhanced expression of circ_0002672 in hepatocellular carcinoma indicates poor prognosis and facilitates cell progression by sponging miR-646. J Cell Biochem 2019.

Liu H, Xue L, Song C, Liu F, Jiang T, Yang X. Overexpression of circular RNA circ_001569 indicates poor prognosis in hepatocellular carcinoma and promotes cell growth and metastasis by sponging miR-411-5p and miR-432-5p. Biochem Biophys Res Commun 2018;503:2659–2665.

Yu J, Yang M, Zhou B, Luo J, Zhang Z, Zhang W, et al. circRNA-10471 acts as competing endogenous RNA and promotes hepatocellular carcinoma progression through microRNA-218-5p/TPXND5 signaling pathway. Clin Sci (Lond) 2019;133:1487–1503.

Zhu Q, Lu G, Luo Z, Gui F, Wu J, Zhang D, et al. CircRNA_circ_0067934 promotes tumor growth and metastasis in hepatocellular carcinoma through regulating miR-1248/FOXO3a/WT1/β-catenin axis. Biochem Biophys Res Commun 2018;497:626–632.

Zhang S, Liu Y, Liu Z, Zhang Y, Chen G, Li K, et al. CircRNA_circ_0005052 promotes hepatocellular carcinoma metastasis and inhibits apoptosis through targeting microRNA-124-1. J BUON 2019;24:2402–2410.

Luo Z, Mao X, Cui W. Circular RNA expression and circPITPMR promotes proliferation and migration in hepatocellular carcinoma. Med Oncol 2020;37:1606–1616.

Zhao F, Liu Y, Xu C, Bao H. Circ RNA hsa_circ_0027089 is a biomarker for hepatocellular carcinoma. J Thyroid Res 2012;2012:14574–14578.

Zhu K, Zhan H, Peng Y, Yang L, Gao Q, Jia H, et al. Plasma hsa_circ_0027089 is a diagnostic biomarker for hepatitis B virus-related hepatocellular carcinoma. Carcinogenesis 2020;41:296–302.

Xu L, Zhang M, Zheng X, Yi P, Lan C, Xu M. The circular RNA cirs-7 (Cdr1as) acts as a risk factor of hepatic microvascular invasion in hepatocellular carcinoma. J Cancer Res Clin Oncol 2017;143:17–27.

Zhang J, Chang Y, Xu L, Qin L. Elevated expression of circular RNA circ_0008450 predicts dismal prognosis in hepatocellular carcinoma and regulates cell proliferation, apoptosis, and invasion via sponging miR-548p. J Cell Biochem 2019;120:9487–9494.

Yang G, Wang X, Liu B, Lu Z, Xu Z, Xu P, et al. circ-BIRC6, a circular RNA, promotes hepatocellular carcinoma progression by targeting the miR-196/212 axis. Cell Cycle 2019;18:976–980.
Wang G, Liu W, Zou Y, Wang G, Deng Y, Luo J, et al. Three isoforms of exosomal circPTGR1 promote hepatocellular carcinoma metastasis via the miR449a-MET pathway. EBioMedicine 2019;40:432–445.

Jiang XM, Li ZL, Li JL, Xu Y, Leng KM, Cui YE, et al. A novel prognostic biomarker for cholangiocarcinoma: circRNA Cdr1as. Eur Rev Med Pharmacol Sci 2018;22:365–371.

Qin M, Liu G, Huo X, Tao X, Sun X, Ge Z, et al. Hsa_circ_0001649: a circular RNA and potential novel biomarker for hepatocellular carcinoma. Cancer Biomark 2016;16:161–169.

Zhang X, Qiu S, Luo P, Zhou H, Jing W, Liang C, et al. Down-regulation of hsa_circ_0001649 in hepatocellular carcinoma predicts a poor prognosis. Cancer Biomark 2018;22:135–142.

Yao Z, Luo J, Hu K, Lin J, Huang H, Wang Q, et al. ZKSCAN1 gene and its related circular RNA (circZKSCAN1) both inhibit hepatocellular carcinoma cell growth, migration, and invasion but through different signaling pathways. Mol Oncol 2017;11:422–437.

Jiang Z, Shen L, Wang S, Wu S, Hu Y, Guo J, et al. Hsa_circ_0028502 and hsa_circ_0076251 are potential novel biomarkers for hepatocellular carcinoma. Cancer Biomark 2018;22:365–371.

Zhong L, Wang Y, Cheng Y, Wang W, Lu B, Zhu L, et al. Circular RNA circC3P1 suppresses hepatocellular carcinoma growth and metastasis through miR-4641/PCK1 pathway. Biochem Biophys Res Commun 2018;499:1044–1049.

Wang YG, Wang T, Ding M, Xiang SH, Shi M, Zhai B. hsa_circ_0091570 acts as a ceRNA to suppress hepatocellular cancer progression by sponging hsa-miR-1307. Cancer Lett 2019;460:128–138.

Luo Y, Fu Y, Huang R, Gao M, Liu F, Gui R, et al. CircRNA_101505 sensitizes hepatocellular carcinoma cells to cisplatin by sponging miR-103 and promotes oxidized-nitro domain-containing protein 1 expression. Cell Death Discov 2019;5:121.

Qiu L, Huang Y, Li Z, Dong X, Chen G, Xu H, et al. Circular RNA profiling identifies circADAMTS13 as a miR-484 sponge which suppresses cell proliferation in hepatocellular carcinoma. Mol Oncol 2019;13:441–455.

Tan Y, Du B, Zhan Y, Wang K, Wang X, Chen B, et al. Antitumor effects of circ-EPHB4 in hepatocellular carcinoma via inhibition of HIF-1alpha. Mol Carcinog 2019;58:875–886.

Li Z, Zhou Y, Yang G, He S, Qiu X, Zhang L, et al. Using circular RNA SMARCA5 as a potential novel biomarker for hepatocellular carcinoma. Clin Chim Acta 2019;492:37–44.

Sun S, Wang W, Luo X, Li Y, Liu B, Li X, et al. Circular RNA circ-ADD3 inhibits hepatocellular carcinoma metastasis through facilitating EZH2 degradation via CDK1-mediated ubiquitination. Am J Cancer Res 2019;9:1695–1707.

Zhang X, Zhou H, Jing W, Luo P, Qiu S, Liu X, et al. The circular RNA hsa_circ_001445 regulates the proliferation and migration of hepatocellular carcinoma and may serve as a diagnostic biomarker. Dis Markers 2018;2018:3073467.

Chen W, Quan Y, Fan S, Wang H, Liang J, Huang L, et al. Exosome-transmitted circular RNA hsa_circ_0051443 suppresses hepatocellular carcinoma progression. Cancer Lett 2020;475:119–128.